4.6 Article

Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 288, 期 46, 页码 33156-33170

出版社

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M113.472506

关键词

Cell Migration; ERK; Histone Deacetylase; MAP Kinases (MAPKs); Protein Phosphorylation

资金

  1. National Institutes of Health Grant from the NCI [R01CA164147]
  2. James Esther King Biomedical Research Program [09KN-17]
  3. a Moffitt Lung SPORE career development grant
  4. Ovarian Cancer Research Fund
  5. University of South Florida graduate student success diversity fellowship

向作者/读者索取更多资源

Background: HDAC6 plays an important role in cell migration. Results: ERK interacts with and phosphorylates HDAC6 to promote cell migration. Conclusion: ERK signaling pathway promotes cell migration, in part, through phosphorylating HDAC6. Significance: Inhibition of HDAC6 activity as well as the EGFR-Ras-Raf-MEK-ERK signaling pathway may cooperatively reduce cell migration. Histone deacetylase 6 (HDAC6) is well known for its ability to promote cell migration through deacetylation of its cytoplasmic substrates such as -tubulin. However, how HDAC6 itself is regulated to control cell motility remains elusive. Previous studies have shown that one third of extracellular signal-regulated kinase (ERK) is associated with the microtubule cytoskeleton in cells. Yet, no connection between HDAC6 and ERK has been discovered. Here, for the first time, we reveal that ERK binds to and phosphorylates HDAC6 to promote cell migration via deacetylation of -tubulin. We have identified two novel ERK-mediated phosphorylation sites: threonine 1031 and serine 1035 in HDAC6. Both sites were phosphorylated by ERK1 in vitro, whereas Ser-1035 was phosphorylated in response to the activation of EGFR-Ras-Raf-MEK-ERK signaling pathway in vivo. HDAC6-null mouse embryonic fibroblasts rescued by the nonphosphorylation mimicking mutant displayed significantly reduced cell migration compared with those rescued by the wild type. Consistently, the nonphosphorylation mimicking mutant exerted lower tubulin deacetylase activity in vivo compared with the wild type. These data indicate that ERK/HDAC6-mediated cell motility is through deacetylation of -tubulin. Overall, our results suggest that HDAC6-mediated cell migration could be governed by EGFR-Ras-Raf-MEK-ERK signaling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Cell Biology

Blocking autophagy to starve pancreatic cancer

Kirsten L. Bryant, Channing J. Der

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)

Retraction Biochemistry & Molecular Biology

撤稿声明: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress (Retraction Article, vol 16, pg 2466, 2006) (Retraction of Vol 16, Pg 2466, 2006)

Pat P. Ongusaha, Hyung-Gu Kim, Sarah A. Boswell, Anne J. Ridley, Channing J. Der, G. Paolo Dotto, Young-Bum Kim, Stuart A. Aaronson, Sam W. Lee

CURRENT BIOLOGY (2019)

Article Biochemistry & Molecular Biology

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

Devon R. Blake, Angelina V. Vaseva, Richard G. Hodge, McKenzie P. Kline, Thomas S. K. Gilbert, Vikas Tyagi, Daowei Huang, Gabrielle C. Whiten, Jacob E. Larson, Xiaodong Wang, Kenneth H. Pearce, Laura E. Herring, Lee M. Graves, Stephen V. Frye, Michael J. Emanuele, Adrienne D. Cox, Channing J. Der

SCIENCE SIGNALING (2019)

Editorial Material Oncology

RAS Mutations Are Not Created Equal

G. Aaron Hobbs, Channing J. Der

CANCER DISCOVERY (2019)

Article Biochemistry & Molecular Biology

The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells

Hua Yang, Shengyan Xiang, Aslamuzzaman Kazi, Said M. Sebti

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Article Multidisciplinary Sciences

Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders

Yao-Cheng Li, Nikki K. Lytle, Seth T. Gammon, Luke Wang, Tikvah K. Hayes, Margie N. Sutton, Robert C. Bast, Channing J. Der, David Piwnica-Worms, Frank McCormick, Geoffrey M. Wahl

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Review Biochemistry & Molecular Biology

RAS, wanted dead or alive: Advances in targeting RAS mutant cancers

Clint A. Stalnecker, Channing J. Der

SCIENCE SIGNALING (2020)

Article Cell Biology

The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53

Chen Hu, Mu Zhang, Niko Moses, Cong-li Hu, Lisa Polin, Wei Chen, Hyejeong Jang, Joshua Heyza, Agnes Malysa, Joseph A. Caruso, Shengyan Xiang, Steve Patrick, Paul Stemmer, Zhenkun Lou, Wenlong Bai, Chuangui Wang, Gerold Bepler, Xiaohong Mary Zhang

CELL DEATH & DISEASE (2020)

Article Cell Biology

HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1

Niko Moses, Mu Zhang, Jheng-Yu Wu, Chen Hu, Shengyan Xiang, Xinran Geng, Yue Chen, Wenlong Bai, You-Wei Zhang, Gerold Bepler, Xiaohong Mary Zhang

Review Biochemistry & Molecular Biology

The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction

Jennifer E. Klomp, Jeff A. Klomp, Channing J. Der

Summary: The RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade is extensively studied and targeted by pharmaceutical industry. The ERK-MAPK cascade, initially thought to be a linear pathway, is now understood as a complex network with dynamic signaling inputs and outputs. Despite advances in understanding, the adaptability of cancer cells to inhibition of key nodes reveals a complexity that is not fully understood.

BIOCHEMICAL SOCIETY TRANSACTIONS (2021)

Article Oncology

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer

Aslamuzzaman Kazi, Liwei Chen, Shengyan Xiang, Rajanikanth Vangipurapu, Hua Yang, Francisca Beato, Bin Fang, Terence M. Williams, Kazim Husain, Patrick Underwood, Jason B. Fleming, Mokenge Malafa, Eric A. Welsh, John Koomen, Jose Trevino, Said M. Sebti

Summary: The study revealed that the dependency of pancreatic cancer cells on mutant KRas is driven by the cyclin-dependent kinase (CDK) network, with knocking out CDK targets showing similar effects as knocking out KRas. The CDK inhibitor AT7519 was identified as a potent inducer of apoptosis in mutant KRas-dependent human cancer cells, demonstrating a link between CDK hyperactivation and mutant KRas dependency. This pharmacological approach was shown to effectively inhibit mutant KRas-driven pancreatic cancer in relevant models, suggesting potential for clinical investigations of AT7519 in patients with pancreatic cancer.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin

Wen-Hsuan Chang, Thuy-Tien Thi Nguyen, Chia-Hsin Hsu, Kirsten L. Bryant, Hong Jin Kim, Haoqiang Ying, Jon W. Erickson, Channing J. Der, Richard A. Cerione, Marc A. Antonyak

Summary: KRAS mutations lead to the production of exosomes enriched with the cell survival protein Survivin, which enhance cancer cell survival and resistance to chemotherapy drugs. Targeting Survivin within these exosomes could potentially serve as a therapeutic strategy for KRAS-dependent cancers.

CANCER LETTERS (2021)

Review Biochemistry & Molecular Biology

The CMG helicase and cancer: a tumor engine and weakness with missing mutations

Shengyan Xiang, Damon R. Reed, Mark G. Alexandrow

Summary: The CMG helicase is an important protein complex involved in DNA replication in mammalian cells. It plays a role in DNA melting and unwinding and is regulated by growth factors and signaling factors. Dysregulation of CMG can lead to genomic instability and contribute to tumorigenesis. This review aims to explore the regulation of CMG during its assembly and activation and highlights its potential as a therapeutic target in cancer.

ONCOGENE (2023)

Editorial Material Oncology

Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers

Adrienne D. Cox, Jenny P. -Y. Ting, Channing J. Der

Summary: Hattori and colleagues developed drug-peptide conjugates using targeted small-molecule covalent inhibitors to generate cancer neoantigens, inducing an immune response against oncogene-mutant cancer cells. This immunotherapy strategy shows potential in overcoming treatment-induced resistance commonly observed in small molecule-based targeted anticancer drugs.

CANCER DISCOVERY (2023)

暂无数据